The Business Model (How They Make Money)

Johnson & Johnson (JNJ) is a global healthcare giant that primarily makes its money by creating and selling cutting-edge medicines and medical technologies. Think of them as a two-part business focused on improving health worldwide. They used to have a consumer health division with well-known brands like Tylenol and Band-Aid, but they spun that off into a separate company called Kenvue in 2023 to focus more intensely on their core healthcare segments.

Their business is now mainly split into two big sections:

1. Innovative Medicine (Pharmaceuticals): This is where JNJ develops and sells prescription drugs to treat a variety of complex diseases. They have a strong focus on areas like cancer (Oncology) and conditions related to the immune system (Immunology). This part of the business brought in a significant $56.964 billion in revenue in fiscal year 2024, making up about 64.1% of their total sales.
2. MedTech (Medical Devices): In this segment, JNJ creates and sells a wide range of medical devices used by doctors, hospitals, and surgical centers. This includes things like surgical tools, joint replacements, and other advanced medical equipment that help patients and healthcare professionals. This section generated $31.857 billion in revenue in fiscal year 2024, accounting for approximately 35.9% of their overall business.

So, essentially, Johnson & Johnson's economic engine is driven by constantly innovating and bringing new, effective drugs and medical devices to market to address significant health challenges.

The Metrics That Matter Most

For a company like Johnson & Johnson, which relies heavily on scientific breakthroughs and a strong product pipeline, here are the most important financial metrics to watch:

1. Revenue: This simply tells you the total amount of money JNJ takes in from selling its medicines and medical devices. For JNJ, revenue growth shows how well they are launching new products and expanding the sales of existing ones across their Innovative Medicine and MedTech segments. Strong and consistent revenue growth indicates that their products are in demand and their market reach is expanding.
2. Net Income: This metric shows the company's actual profit after all expenses, including operating costs, interest on debt, and taxes, have been paid. For JNJ, a healthy net income demonstrates their ability to manage costs effectively and turn their sales into real earnings for shareholders. It's the ultimate measure of how profitable the business truly is.
3. R&D Expenses (Research & Development Expenses): This is the money JNJ pours into discovering and developing new drugs and medical technologies. For a company in pharmaceuticals and medical devices, R&D is incredibly important because it's the lifeblood of their future growth. In 2024, JNJ's Innovative Medicine segment alone invested $13.53 billion in R&D, which was about 23.7% of that segment's sales. A strong commitment to R&D suggests the company is actively working on future breakthroughs, which is crucial for long-term success in the healthcare industry.
4. Free Cash Flow: Think of Free Cash Flow as the leftover cash a business has after paying for all its operations and investing in itself (like buying new equipment or building new facilities). For JNJ, this metric is vital because it shows how much cash the company generates that can be used for things like paying dividends to shareholders, buying back its own stock, or making strategic acquisitions. A robust Free Cash Flow indicates financial strength and flexibility.
5. Gross Margin: This metric tells you how much profit JNJ makes from selling its products after subtracting the direct costs of making those products (like raw materials and manufacturing). For JNJ, with its diverse portfolio of medicines and devices, a healthy gross margin shows that their core products are profitable at their most basic level. It helps investors understand the pricing power of their drugs and devices and the efficiency of their production processes before other operating expenses are factored in.

How to Value This Company

The ONE most relevant valuation metric for Johnson & Johnson is the P/E ratio (Price-to-Earnings ratio).

Here's why and how to use it:

The P/E ratio is a very common way to figure out if a stock is cheap or expensive, especially for a large, stable company like JNJ that typically has consistent profits. It simply compares the company's current stock price to its earnings per share (the profit it makes for each share of stock).

To use it, you take the current stock price and divide it by the company's earnings per share over the last year.

• If JNJ's P/E ratio is lower than its historical average P/E or the average P/E of similar, stable healthcare companies, it might suggest the stock is undervalued or "cheap."
• If JNJ's P/E ratio is higher than its historical average or its peers, it might suggest the stock is overvalued or "expensive."

Because Johnson & Johnson is a mature company that aims for steady, predictable earnings from its established drug and device portfolio, the P/E ratio gives you a straightforward way to gauge how much investors are willing to pay for each dollar of the company's earnings. It helps you quickly compare its current valuation to how it's been valued in the past and against other companies in its league.